Haemodialysis (HD) requires safe and effective anticoagulation to prevent clot formation within the extracorporeal circuit during dialysis treatments to enable adequate dialysis and minimise adverse events, including major bleeding. Low molecular weight heparin (LMWH) may provide a more predictable dose, reliable anticoagulant effects and be simpler to administer than unfractionated heparin (UFH) for HD anticoagulation, but may accumulate in the kidneys and lead to bleeding. in this latest episode fo the podcast Edmund Chung, Knowledge and Information Decimation Editor of the Cochrane Kidney Transplant Group. Edmund is Joined by the lead author on
this article Patricia Natale Sydney School of Public Health, The University of Sydney.